文献速递妇科

WEE1抑制剂adavosertib联合卡铂治疗晚期TP53突变卵巢癌:一项生物标志物富集的II期研究

WEE1 inhibitor adavosertib in combination with carboplatin in advanced TP53 mutated ovarian cancer: A biomarker-enriched phase II study.
PubMed 文献 · Gynecol Oncol · 2023-05-24

本II期开放标签非随机研究纳入32例TP53突变铂耐药卵巢癌患者,给予卡铂AUC 5静脉给药联合adavosertib 225 mg每日两次口服2.5天、21天为一周期。可评估疗效29例,客观缓解率41%(95%CI 23%-61%),中位无进展生存期5.6个月(95%CI 3.8-10.3)。骨髓毒性、恶心呕吐为最常见不良事件,骨髓毒性是剂量减量和延迟最常见原因。

要点

  • 可评估患者客观缓解率为41%(95%CI 23%-61%),中位无进展生存期5.6个月(95%CI 3.8-10.3)。
  • 骨髓毒性、恶心呕吐为最常见不良事件,骨髓毒性是剂量减量和延迟最常见原因。
  • CCNE1扩增患者疗效略好但无统计学显著差异。

核心结论

  • adavosertib 225 mg每日两次口服2.5天联合卡铂AUC 5可安全联合并在铂耐药卵巢癌患者中显示抗肿瘤疗效,但骨髓毒性仍是关注点,因其是剂量减量和剂量延迟最常见原因。

研究设计与样本

  • II期、开放标签、非随机研究(NCT01164995),纳入32例TP53突变铂耐药卵巢癌患者,中位年龄63岁(范围39-77岁),其中29例可评估疗效。
  • 给药方案为卡铂AUC 5 mg/ml·min静脉给药联合adavosertib 225 mg每日两次口服2.5天,21天为一周期。
  • 主要目标为确定卡铂联合adavosertib的疗效和安全性,次要目标包括无进展生存期、循环肿瘤细胞变化及基因组改变探索。

主要发现

  • 可评估疗效的29例患者中,12例最佳疗效为部分缓解,客观缓解率为41%(95%CI 23%-61%)。
  • 中位无进展生存期为5.6个月(95%CI 3.8-10.3)。
  • 骨髓毒性、恶心和呕吐为最常见不良事件。
  • CCNE1扩增患者疗效略好但无统计学显著差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: In the first part of this phase II study (NCT01164995), the combination of carboplatin and adavosertib (AZD1775) was shown to be safe and effective in patients with TP53 mutated platinum-resistant ovarian cancer (PROC). Here, we present the results of an additional safety and efficacy cohort and explore predictive biomarkers for resistance and response to this combination treatment. METHODS: This is a phase II, open-label, non-randomized study. Patients with TP53 mutated PROC received carboplatin AUC 5 mg/ ml·min intravenously and adavosertib 225 mg BID orally for 2.5 days in a 21-day cycle. The primary objective is to determine the efficacy and safety of carboplatin and adavosertib. Secondary objectives include progression-free survival (PFS), changes in circulating tumor cells (CTC) and exploration of genomic alterations. RESULTS: Thirty-two patients with a median age of 63 years (39-77 years) were enrolled and received treatment. Twenty-nine patients were evaluable for efficacy. Bone marrow toxicity, nausea and vomiting were the most common adverse events. Twelve patients showed partial response (PR) as best response, resulting in an objective ORR of 41% in the evaluable patients (95% CI: 23%-61%). The median PFS was 5.6 months (95% CI: 3.8-10.3). In patients with tumors harboring CCNE1 amplification, treatment efficacy was slightly but not significantly better. CONCLUSIONS: Adavosertib 225 mg BID for 2.5 days and carboplatin AUC 5 could be safely combined and showed anti-tumor efficacy in patients with PROC. However, bone marrow toxicity remains a point of concern, since this is the most common reason for dose reductions and dose delays.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Embaby A, Kutzera J, Geenen JJ, et al. WEE1 inhibitor adavosertib in combination with carboplatin in advanced TP53 mutated ovarian cancer: A biomarker-enriched phase II study. Gynecol Oncol. 2023. PMID: 37236033. doi:10.1016/j.ygyno.2023.05.063

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。